SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 10,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $6.92, for a total value of $69,200.00. Following the transaction, the insider directly owned 600,887 shares in the company, valued at approximately $4,158,138.04. This represents a 1.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $6.30 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a fifty-two week low of $2.96 and a fifty-two week high of $7.21. The firm has a 50-day simple moving average of $5.54 and a 200 day simple moving average of $5.12. The company has a market cap of $528.51 million, a PE ratio of -5.48 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 153.15% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, above the approximately $93.4 million consensus estimate, implying 22%–24% year-over-year growth. Management also continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook and EBITDA breakeven article
• Positive Sentiment: The company announced a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement could expand SOPH’s role in oncology testing and support longer-term revenue growth. AstraZeneca collaboration article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and maintained a Buy rating, while BTIG lifted its target from $8 to $9 and also kept a Buy rating. The revisions indicate improving analyst confidence in SOPH’s growth outlook. Analyst price target updates
• Positive Sentiment: Second-quarter revenue increased 27% year over year to $23.3 million, exceeding expectations of $21.7 million, while the adjusted EBITDA loss improved 27% to $8.8 million. Second-quarter 2026 results article
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares for about $242,350 under pre-arranged Rule 10b5-1 plans. The sales reduced their holdings only modestly, limiting their signaling value.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, missing the $0.21-loss consensus estimate by $0.05. Net loss remained $22.4 million, and gross margin declined from the prior-year period, underscoring continuing profitability concerns. Quarterly earnings report

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the 4th quarter valued at $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at about $55,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. BTIG Research increased their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.